14,15-epoxy-5,8,11-eicosatrienoic acid has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, X; Gao, T; Li, X; Lin, L; Liu, S; Luo, P; Qin, X; Sun, A; Wang, X; Wu, Q; Zhu, X | 1 |
1 other study(ies) available for 14,15-epoxy-5,8,11-eicosatrienoic acid and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates MPTP-Induced Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8,11,14-Eicosatrienoic Acid; Adamantane; Animals; Behavior, Animal; Cell Survival; Cells, Cultured; Dopaminergic Neurons; Epoxide Hydrolases; Lauric Acids; Male; Mice, Inbred C57BL; Mice, Knockout; Neuroprotective Agents; Paraquat; Parkinsonian Disorders; Rotarod Performance Test; Solubility; Substantia Nigra; Tyrosine 3-Monooxygenase; Up-Regulation | 2015 |